Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Tianjin Tianyao Pharmaceuticals Co., Ltd. (600488.SS)
Tianjin, CN
Tianjin Tianyao Pharmaceuticals Co., Ltd. is a Chinese enterprise primarily engaged in the research, manufacturing, and export of active pharmaceutical ingredients (APIs) across the Asian market. The company's core product offerings include APIs and formulated drugs for corticosteroid, cardio cerebrovascular, and analgesic applications. Its extensive portfolio of bulk drug substances encompasses numerous compounds such as dexamethasone and its various salts and esters, prednisone, prednisolone, flucinonide, halcinonide, triamcinolone and its derivatives, clobetasol propionate, betamethasone, and methylprednisolone. Based in Tianjin, China, Tianjin Tianyao Pharmaceuticals Co., Ltd. (SHSE: 600488) operates as a subsidiary of Jinhushen Biomedical Technology Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +9.92% | +2.97% | -2.81% | +30.05% | +27.65% | +35.45% | +30.97% | -4.48% | +14.94% | -3.48% | -5.78% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-9.6% Q1'26: -22.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-45.8% Q1'26: -76.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-0.3% Q1'26: -3.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+4.9% Q1'26: +4.0% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+3.8% Q1'26: +1.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.8% ★ Q1'26: -0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.60× ★ Q1'26: 7.85× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
|---|---|---|
| Revenue |
2.43B
est: 2.28B (+6.4%)
|
3.33B
est: 2.56B (+29.9%)
|
| EBITDA |
368.33M
est: 274.85M (+34.0%)
|
488.76M
est: 308.72M (+58.3%)
|
| EBIT |
242.20M
est: 115.64M (+109.4%)
|
326.66M
est: 129.89M (+151.5%)
|
| Net Income |
145.23M
|
161.77M
|
| SGA |
802.31M
est: 672.00M (+19.4%)
|
1.09B
est: 754.81M (+44.8%)
|
| EPS |
0.13
|
0.15
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | B- | 3/5 | 3/5 | 3/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | B | 3/5 | 4/5 | 3/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | B | 3/5 | 4/5 | 3/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 228.3K | 0.06% |
| 2 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 13.2K | 0.26% |
| 3 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 5.8K | 0.48% |
| 4 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 650.3K | 0.06% |
| 5 | Vanguard Total World Stock ETF VT | 0.00% | 282.3K | 0.06% |
| 6 | Vanguard ESG International Stock ETF VSGX | 0.00% | 15.2K | 0.10% |
| 7 | Vanguard Total International Stock ETF VXUS | 0.00% | 884.1K | 0.05% |
| 8 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 1.0K | 0.22% |
| 9 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 3.1K | 0.22% |
| 10 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.7K | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bo Liu | Board of Directors Secretary | — | male |
| Hao Liu | Deputy GM & Director | — | male |
| Jie Zhang | Deputy General Manager | — | male |
| Liyan Zhu | Chief Financial Officer & Director | — | male |
| Shuxiang Li | GM & Director | — | male |
| Xiaoyan Yang | Deputy General Manager | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600488.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
